Compassionate use of linezolid for adult taiwanese patients with bone and joint infections

Chemotherapy

Volumn 56, Issue 6, 2010, Pages 429-435

  Lu, Po Liang ^a,b,c   Wang, Jann Tay ^e,f   Chen, Chih Jung ^g,h   Chen, Wan Chin ^h   Chen, Tun Chieh ^a,c   Hwang, Yhu Chering ^f,g   Chang, Shan Chwen ^d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^g CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^h CENTER FOR DISEASE CONTROL   (Taiwan)

Author keywords

Joint infections; Linezolid; Osteomyelitis

Indexed keywords

ALANINE AMINOTRANSFERASE; CEFAZOLIN; CIPROFLOXACIN; COTRIMOXAZOLE; CREATININE; FUSIDIC ACID; GENTAMICIN; LINEZOLID; OXACILLIN; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; BONE AND JOINT INFECTIONS; COMPASSIONATE USE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT REFUSAL; URINARY TRACT DISEASE;

ACETAMIDES; ADULT; ANTI-INFECTIVE AGENTS; ARTHRITIS, INFECTIOUS; COMPASSIONATE USE TRIALS; FEMALE; HUMANS; MALE; OSTEOMYELITIS; OXAZOLIDINONES; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 78349274628     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317752     Document Type: Article

References (27)

1. Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ: Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 2007; 29: 233-239
2. Sparo MD, Jones DG, Sánchez Bruni SF: Assessment of the in vitro efficacy of the novel antimicrobial peptide CECT7121 against human Gram-positive bacteria from serious infections refractory to treatment. Chemotherapy. 2009; 55: 270-277
3. Trautmann M, Stecher J, Hemmer W, Luz K, Panknin HT: Intranasal mupirocin prophylaxis in elective surgery: a review of published studies. Chemotherapy 2008; 54: 9-16
4. Kutscha-Lissberg F, Hebler U, Muhr G, Koller M: Linezolid penetration into bone and joint tissues infected with methicillinresistant staphylococci. Antimicrob Agents Chemother 2003; 47: 3964-3966
5. Aneziokoro CO, Cannon JP, Pachucki CT, Lentino JR: The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother 2005; 17: 643-650
6. Bassetti M, Vitale F, Melica G, Righi E, Di Biagio A, Molfetta L, Pipino F, Cruciani M, Bassetti D: Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother 2005; 55: 387-390 (Pubitemid 40425467)
7. Chen CJ, Chiu CH, Lin TY, Lee ZL, Yang WE, Huang YC: Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 2007; 26: 985-988
8. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML: Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-528
9. Kosaka T, Kokufu T, Shime N, Sugioka N, Kato R, Hamaoka K, Fujita N: Pharmacokinetics and tolerance of linezolid for meticillin- resistant Staphylococcus aureus mediastinitis in paediatric patients. Int J Antimicrob Agents 2009; 33: 368-370
10. Papadopoulos A, Plachouras D, Giannitsioti E, Poulakou G, Giamarellou H, Kanellakopoulou K: Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study. J Chemother 2009; 21: 165-169
11. Rao N, Hamilton CW: Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007; 59: 173-179
12. Rao N, Ziran BH, Hall RA, Santa ER: Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res 2004: 67-71
13. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ: Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004; 32: 8-14
14. Razonable RR, Osmon DR, Steckelberg JM: Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004; 79: 1137-1144
15. Senneville E, Legout L, Valette M, Yazdanpanah Y, Giraud F, Beltrand E, Obert G, Dubreuil L, Migaud H, Mouton Y: Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother 2004; 54: 798-802
16. Lipsky BA, Itani K, Norden C: Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin- clavulanate. Clin Infect Dis 2004; 38: 17-24
17. Falagas ME, Siempos, II, Vardakas KZ: Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomized controlled trials. Lancet Infect Dis 2008; 8: 53-66
18. Falagas ME, Manta KG, Ntziora F, Vardakas KZ: Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006; 58: 273-280
19. Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, Remington J: Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003; 47: 1824-1831
20. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement (m100-s17). Wayne, Clinical and Laboratory Standards Institute, 2007
21. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ: Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36: 159-168
22. Till M, Wixson RL, Pertel PE: Linezolid treatment for osteomyelitis due to vancomycin- resistant Enterococcus faecium . Clin Infect Dis 2002; 34: 1412-1414
23. Stolle LB, Plock N, Joukhadar C, Arpi M, Emmertsen KJ, Buerger C, Riegels-Nielsen P, Kloft C: Pharmacokinetics of linezolid in bone tissue investigated by in vivo microdialysis. Scand J Infect Dis 2008; 40: 24-29
24. Barberan J: Management of infections of osteoarticular prosthesis. Clin Microbiol Infect 2006; 12(suppl 3):93-101
25. Frippiat F, Bergiers C, Michel C, Dujardin JP, Derue G: Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 2004; 53: 1114-1115
26. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ: Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillinresistant staphylococci: results from a randomized clinical trial. Surg Infect 2003; 4: 57-70
27. Sharpe JN, Shively EH, Polk HC Jr: Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus . Am J Surg 2005; 189: 425-428